Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Assertio Holdings, Inc. (ASRT)

2.95   0.04 (1.37%) 11-25 13:00
Open: 2.94 Pre. Close: 2.91
High: 3 Low: 2.9
Volume: 304,606 Market Cap: 142(M)

Technical analysis

as of: 2022-11-25 1:55:15 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 3.52     One year: 4.11
Support: Support1: 2.45    Support2: 2.1
Resistance: Resistance1: 3.01    Resistance2: 3.52
Pivot: 2.81
Moving Average: MA(5): 2.88     MA(20): 2.77
MA(100): 2.81     MA(250): 2.64
MACD: MACD(12,26): 0.1     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 80.8     %D(3): 72.8
RSI: RSI(14): 64.7
52-week: High: 4.44  Low: 1.25
Average Vol(K): 3-Month: 700 (K)  10-Days: 584 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ASRT ] has closed below upper band by 18.7%. Bollinger Bands are 48.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.99 - 3.01 3.01 - 3.02
Low: 2.84 - 2.86 2.86 - 2.87
Close: 2.88 - 2.91 2.91 - 2.94

Company Description

Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.

Headline News

Thu, 24 Nov 2022
Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab - Nasdaq

Wed, 23 Nov 2022
ASRT vs. ZTS: Which Stock Is the Better Value Option? - Nasdaq

Tue, 22 Nov 2022
Should Value Investors Buy Assertio (ASRT) Stock? - Nasdaq

Tue, 15 Nov 2022
Assertio Holdings: Can Management Grow The Business? (NASDAQ:ASRT) - Seeking Alpha

Mon, 14 Nov 2022
Will Assertio Holdings Inc (ASRT) Outperform the Rest of the Stocks in the Healthcare Sector? - InvestorsObserver

Fri, 11 Nov 2022
Briefcase: Radiologic technologist society announces promotions - Albuquerque Journal

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 48 (M)
Shares Float 47 (M)
% Held by Insiders 1.7 (%)
% Held by Institutions 35.6 (%)
Shares Short 5,730 (K)
Shares Short P.Month 5,960 (K)

Stock Financials

EPS 0.52
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.79
Profit Margin (%) 18.4
Operating Margin (%) 39
Return on Assets (ttm) 10.9
Return on Equity (ttm) 22.1
Qtrly Rev. Growth 34.2
Gross Profit (p.s.) 1.98
Sales Per Share 2.88
EBITDA (p.s.) 1.79
Qtrly Earnings Growth 0
Operating Cash Flow 56 (M)
Levered Free Cash Flow 27 (M)

Stock Valuations

PE Ratio 5.56
PEG Ratio 0.2
Price to Book value 1.05
Price to Sales 1.02
Price to Cash Flow 2.54

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.